All Black adults would experience a decrease in reported estimated glomerular filtration rate (eGFR) of 13.7% (computed from the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) race coefficient as 1 − 1/1.159). Median eGFR was 102.9 mL/min/1.73 m2 with race and 88.8 mL/min/1.73 m2 without race; the median eGFR change was −14.1 mL/min/1.73 m2. The 25th percentile for the change in eGFR was −16.5 mL/min/1.73 m2, and the 75th percentile for the change in eGFR was −11.5 mL/min/1.73 m2. Data are from the 2001-2018 National Health and Nutrition Examination Survey (NHANES). eGFRcr indicates estimated glomerular filtration rate from serum creatinine.
eAppendix. Population Definitions and Non-eGFR Inclusion/Exclusion Criteria
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Diao JA, Wu GJ, Taylor HA, et al. Clinical Implications of Removing Race From Estimates of Kidney Function. JAMA. 2021;325(2):184–186. doi:10.1001/jama.2020.22124
Over the past year, medical centers across the US have removed race adjustment from estimated glomerular filtration rate from serum creatinine (eGFRcr), with many now reporting the “White/other” value for all patients. These changes follow calls to reconsider the use of race in estimating kidney function1 and in medicine broadly.2 We analyzed potential changes in recommended care using eGFRcr with and without race among Black individuals in the US (individuals who are not Black would not be affected).
We used data from the National Health and Nutrition Examination Survey (NHANES) characterizing a cross-sectional sample of the noninstitutionalized US population from 2001 to 2018, with response rates from 48.8% to 79.6%. Laboratory measurements, including serum creatinine, were collected in mobile examination centers, and demographic variables, including race/ethnicity, were self-reported in personal interviews. Participants provided written consent using a protocol approved by the National Center for Health Statistics Research Ethics Review Board.
We computed eGFRcr using the Chronic Kidney Disease (CKD) Epidemiology Collaboration (CKD-EPI) equation3 with and without its race coefficient for Black individuals. We then estimated the number of Black adults whose care could change as recommended by Kidney Disease: Improving Global Outcomes (KDIGO)3 and the Medicare Part B benefit policy.4 Evaluated changes include CKD diagnoses, CKD stage reclassifications and related drug recommendations, nephrologist referrals, Medicare coverage, kidney donation, and kidney transplantation. Outcomes are defined in the eAppendix in the Supplement. Analyses were performed using R version 4.0.0.
The study cohort comprised 9522 nonpregnant, non-Hispanic Black adults; 50.5% self-identified as women and the median age was 45 years. After removal of race, median eGFR decreased from 102.9 mL/min/1.73 m2 to 88.8 mL/min/1.73 m2; the median change was −14.1 mL/min/1.73 m2 (Figure).
Removing race may increase the prevalence of CKD among Black adults from 14.9% to 18.4% (difference, 3.5% [95% CI, 3.2%-3.9%]) (Table). Concurrently, 29.1% (95% CI, 26.4%-32.0%) of Black adults with existing CKD may be reclassified to more severe stages of disease, with significant clinical and pharmacologic implications. Affected drugs include angiotensin-converting enzyme inhibitors, β-blockers, warfarin, cisplatin, metformin, and sodium-glucose cotransporter-2 inhibitors. The prevalence of CKD stage 3b or higher may change from 2.3% to 3.5%, affecting 1.2% (95% CI, 1.0%-1.5%) of Black adults. Similarly, the prevalence of CKD stage 4 or higher may change from 1.0% to 1.3%, affecting 0.29% (95% CI, 0.18%-0.43%) of Black adults.
Following race removal, 3.4% of Black adults may be referred to specialist care instead of 3.2% (difference, 0.22% [95% CI, 0.13%-0.35%]). Medicare would cover 5.5% of Black adults for medical nutrition therapy instead of 5.0% (difference, 0.47% [95% CI, 0.37%-0.60%]). Similarly, 0.36% of Black adults would be covered for kidney disease education instead of 0.22% (difference, 0.14% [95% CI, 0.07%-0.25%]).
Computing eGFRcr without race may raise the proportion of Black adults eligible for the kidney transplant wait list from 0.66% to 0.71%, newly qualifying 0.051% (95% CI, 0.02%-0.10%) of Black adults for transplantation. Conversely, the proportion of kidney donor candidates deemed “not acceptable” would change from 38.5% to 40.6%, newly disqualifying 2.1% (95% CI, 1.8%-2.4%) of Black adults from kidney donation.
Removal of race adjustment may increase CKD diagnoses among Black adults and enhance access to specialist care, medical nutrition therapy, kidney disease education, and kidney transplantation, while potentially excluding kidney donors and prompting drug contraindications or dose reductions for individuals reclassified to advanced stages of CKD. This potential for benefits and harms must be interpreted in light of persistent disparities in care,3 documented biases of eGFRcr without race,5 and the historical misuse of race as a biological variable to further racism.2
This study had several limitations. First, many institutions use the Modification of Diet in Renal Disease (MDRD) equation. Removal of the larger race coefficient in the MDRD (1.212 vs 1.159 in CKD-EPI) would lead to larger decreases in eGFR and more individuals crossing relevant thresholds. Second, some institutions have removed race using methods other than universalizing the “White/other” equation. Third, eGFR does not determine care for all patients. Clinical judgment,6 unbiased confirmatory tests to corroborate eGFRcr, and varying adherence to guidelines may all influence how changes materialize.
Corresponding Author: Arjun K. Manrai, PhD, Computational Health Informatics Program, Boston Children’s Hospital, Department of Biomedical Informatics, Harvard Medical School, 401 Park Dr, Boston, MA 02115 (firstname.lastname@example.org).
Accepted for Publication: October 22, 2020.
Published Online: December 2, 2020. doi:10.1001/jama.2020.22124
Author Contributions: Mr Diao and Dr Manrai had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Diao, Wu, Taylor, Powe, Manrai.
Acquisition, analysis, or interpretation of data: Diao, Wu, Tucker, Powe, Kohane, Manrai.
Drafting of the manuscript: Diao, Powe, Manrai.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Diao, Wu, Powe, Manrai.
Obtained funding: Manrai.
Supervision: Kohane, Manrai.
Conflict of Interest Disclosures: Dr Taylor reported receipt of personal fees for consulting services from Novartis, Pfizer, and UnitedHealth Group. No other disclosures were reported.
Funding/Support: Dr Manrai was supported by National Institutes of Health (NIH) award 5K01HL138259.
Role of the Funder/Sponsor: The NIH had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank Andrew S. Levey, MD, and Lesley Inker, MD, MPH, Division of Nephrology, Tufts Medical Center, and Jason K. Wang, MA, Computational Health Informatics Program, Boston Children’s Hospital, for helpful comments on the manuscript. None received compensation for their contributions.
Create a personal account or sign in to: